secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0000882095-22-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance
--------------------------------------------------------------------------------

- Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).
- Biktarvy sales $2.6B (+28% YoY); oncology sales $527M (+71% YoY) driven by cell therapy and Trodelvy.
- HIV product sales $4.2B (+7% YoY); HCV sales $448M (-18% YoY); Veklury sales $445M (-46% YoY).
- FY guidance raised: product sales $24.5-25.0B (prev $23.8-24.3B); non-GAAP EPS $6.35-6.75 (prev $6.20-6.70).
- Operating cash flow $1.8B in Q2; cash & equivalents $7.0B as of June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/0000882095-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000016/gild-20220802.htm
  HTML page:      https://secwatch.observer/filing/0000882095-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer